,ticker,content
0,IQV,relative strength rs rating quintile im iqv enter new percentile thursday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price performance worst best score score show stock price movement last week stack other stock database history reveal best perform stock tend have higher rs rating launch largest price move see quintile im continue rebound hit benchmark look winning stock try simple routinequintile im be build consolidation entry see break volume least higher normal company top line growth fall last quarter ep grow prior report look next report quintile im earn rank peer medical research equipment service industry group illumina ilmn pra health science prah bio techne tech be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
1,IQV,tuesday quintile im iqv get positive adjustment relative strength rs rating exclusive rating investor business daily track share price action worst best score grade show stock price performance last week hold other stock database year market history show best stock tend have rs rating begin biggest climb see quintile im continue show renew price strength hit benchmark look winning stock try simple routinequintile im be build consolidation buy point see break volume least higher normal company see earning sale growth rise last quarter earning share increase revenue rise look next report feb quintile im hold rank peer medical research equipment service industry group pra health science prah be top rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
2,IQV,veeva system veev be coil spring ready jump thank several growth initiative xthat contention canaccord genuity analyst richard davis say veeva stock have have mighty run so far add cloud compute firm focus software application pharmaceutical life science field have room further growth used term coil spring describe veeva outlook davis say future look even more prosperous come view veeva have several growth initiative process range significant new feature upsell adjacent customer breadth move davis say recent note client pleasanton calif base veeva have more customer life science industry range big pharma firm emerge biotechs count company amgen amgn eli lilly lly merck mrk novartis nvs pfizer pfe customer veeva go public october share hit time high march manage avoid most carnage week sell share be friday veeva stock break week consolidation period buy point feb day company post better expect result fiscal fourth quarter give guidance crushed wall street estimate current fiscal year current fiscal year end next jan veeva expect earn adjust share year year sale base midpoint guidance analyst be modele adjust profit share sale veeva growth initiative be likely reach sufficient scale year provide path upside estimate davis say scenario be correct investor figure sometime summer fall point veeva share sustainably move higher say davis rate veeva stock buy veeva begin software application help pharmaceutical sale rep organize drug datum make stronger doctor pitch today product customer relationship management call veeva crm dominate drug market roughly user share now part veeva commercial cloud business big driver company business today be veeva vault launch be create organize content involved clinical drug trial document patient datum work flow vault product now cover clinical quality regulatory commercial aspect drug development manufacturing sale have penetrate less market william blair analyst bhavan suri tell investor business daily veeva also have discover vault offer be useful other heavily regulate industry such chemical consumer product sector company offer company outside life science be call vault qualityone have more company used product launch year get newsletter deliver inbox more info product service privacy policy term useon conference call analyst feb veeva chief executive peter gassner say company have be planting seed future growth especially exciting see franchise re build side life science say veeva be uniquely position help streamline drug development re only technology provider best class application suite major area development include clinical quality regulatory come next year safety single modern cloud platform believe veeva development cloud be industry long term veeva software service offer have be replace legacy vendor use premise hardware software system rival include oracle orcl medidata solution mdso iqv other veeva management have strong track record deliver growth be conservative guidance william blair suri say rate veeva stock outperform veeva have forecast revenue run rate fourth quarter think hit run rate early next year month ahead expectation suri say not only hit dollar run rate early next year sustainability growth be next year meanwhile jpmorgan downgrade veeva stock overweight neutral march cite valuation concern stock have climb year be strong franchise be execute well number growth initiative have little room outperformance current level jpmorgan analyst sterling auty say note client estimate veeva addressable market fraction more spend year life science company information technology fertile market provide greater growth subscription revenue fiscal grow fiscal auty say related veeva rocket top quarterly estimate crush guidance viewsceo gassner make sure veeva have second act more
3,IQV,welcome move catalent ctlt see relative strength rating improve thursday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure market leadership worst best score rating show stock price movement trail week hold other stock database history show best stock typically have rs rating begin biggest climb see catalent continue rebound hit benchmark look winning stock try simple routinecatalent be work consolidation buy point see clear price heavy trading term fundamental catalent have post quarters rise earning growth revenue growth have also moved higher same time frame catalent earn rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term userelated ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
4,IQV,pra health science prah have relative strength rs rating upgrade friday try find best stock buy watch be sure pay attention relative price strength ibd proprietary rating identify market leadership worst best score score show stock price behavior last week compare other stock database history show market biggest winner tend have better rs rating begin biggest price move look best stock buy watch start ibd stock be work flat base entry see clear price volume least higher normal be aware third stage base later stage pattern work have greater failure rate point stock have already climb substantially take look top bottom line number company have post rise ep growth last quarters sale gain have also moved higher same time frame pra health science earn rank peer medical research equipment service industry group illumina ilmn quintile im iqv be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
5,IQV,bio rad lab bio see positive improvement relative strength rs rating thursday upgrade try find best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily identify share price movement worst best score grade show stock price performance last week hold other stock database year market history show stock go make biggest gain typically have rs rating north early stage move look best stock buy watch start herebio rad lab break earlier have fall back prior entry double bottom stock re watch break past buy point then decline more original entry price consider fail base best stock form new consolidation also keep mind most recent pattern be later stage base make riskier establish new position add share exist term fundamental health bio rad lab have post quarters rise earning growth revenue gain have also increase same time frame bio rad lab hold rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
6,IQV,biotech company celgene celg biogen biib gilead science gild put drug extensive trial gain fda approval turn clinical research firm pra health science prah pra health be lead contract research organization hold ranking medical research equipment service industry group ahead
7,IQV,monday myriad genetic mygn earn positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify price movement worst best score rating show stock price movement last week stack other stock database year market history show market biggest winner often have rs rating north launch largest climb see myriad genetic continue rebound hit benchmark look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock be able form consolidation break take look revenue profit performance company have post quarters increase earning growth sale gain have be less impressive come most recent report myriad genetic earn rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
8,IQV,icon iclr see positive improvement relative strength rs rating wednesday rise unique rating identify market leadership show stock price movement last week measure other stock database decade market research show best stock tend have higher rs rating begin biggest climb see icon continue show renew price strength clear threshold look best stock buy watch start hereicon be build consolidation buy point see break volume least higher normal icon report earning growth latest quarterly report sale rise icon hold rank peer medical research equipment service industry group pra health science prah illumina ilmn quintile im iqv be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
9,IQV,welcome move charle river lab international crl see relative strength rating improve wednesday ibd proprietary rating track price action worst best score rating show stock price movement last week compare other stock database decade market research show stock go make biggest gain tend have rs rating north launch largest climb see charle river lab international continue rebound clear threshold see ibd help make more money stockscharle river lab international be work double bottom buy point see stock break volume least higher normal sale growth fall last quarter ep grow prior report charle river lab international hold rank peer medical research equipment service industry group pra health science prah quintile im iqv illumina ilmn be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
10,IQV,pharmaceutical biotech industry be prolific new drug candidate pra health science prah prosper provider clinical development service pra health have be top performer stock market late thank solid fundamental have post accelerate growth earning share last quarters wall street see pattern continue next quarters share be year date friday hit record high intraday stock end regular trading last several quarters seem organic growth pra have be pretty consistently double peer william blair analyst john kreger tell investor business daily be market grow year organic growth have be kreger be modele pra health post sale growth next year baird analyst eric coldwell also sing pra health praise pra have materially outperformed peer average growth rate year almost assuredly continue do so even recent acquisition coldwell tell ibd pra health win business get high mark contract performance coldwell say have strong excuse culture wisdom know market business avoid add point hasn make problematic acquisition large peer lead contract research organization pra health provide service pharmaceutical company raleigh base company have participate clinical trial worldwide trial have lead food drug administration international regulatory approval more drug pra health compete such company iqv icon iclr inc research incr other pra health have be ahead curve major trend industry keybanc capital market analyst donald hooker tell ibd be earlier mover peer provide functional outsource service drug company functional service provider pra health handle entire operation company drug testing approval rather specific drug company score such deal takeda pharmaceutical japan september win major account unnamed customer early pra health also be ahead rival provide datum service help clinical drug test plan management even eventual pricing launch predictivv platform september pra health acquire symphony health solution privately hold provider datum analytic consult service life science market symphony help drug company better track understand performance use product pra health paid upfront potential contingent payment base symphony exceed financial target month period end december symphony provide pra health state art cloud compute infrastructure datum be store common platform used very agile way hooker say symphony acquisition give additional cross selling opportunity add coldwell ibd take pra health science currently rank ibd list top perform growth stock more analysis pra visit ibd stock checkup contract research organization field have be consolidate activity be likely continue analyst say inc research close merger inventiv health aug be create november follow october merger im health quintile pra health have be gain market share big rival digest acquisition analyst say continue serve broad range client small development stage biotech large biopharma shannon say conference call analyst oct diversity new business award continue be consistent previous quarters approximately new award come pharmaceutical sector approximately come biotechnology sector pra health get revenue clinical research segment datum solution unit include newly acquire symphony third quarter pra health earn adjust cent share higher year year revenue december quarter analyst expect pra health earn share vs year sale pra health have more employee worldwide have more office north america europe asia latin america south africa australia middle east meanwhile pipeline drug candidate come clinical testing look strong keybanc hooker say overall outsource environment clinical trial be really strong right now hooker say capital market be supportive biotech be more drug candidate trial fda be work bring more treatment market say hooker good time be pharma
11,IQV,wednesday charle river lab international crl get positive adjustment relative strength rs rating exclusive rating investor business daily track price performance worst best score grade show stock price behavior last week compare other stock database decade market research show top perform stock tend have rs rating north early stage move see charle river lab international continue show renew price strength hit benchmark look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock be able offer clear proper buy point top bottom line growth moved higher last quarter earning be compare prior report revenue increase company hold rank peer medical research equipment service industry group pra health science prah quintile im iqv catalent ctlt be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
12,IQV,delphi technology plc dlph free report look strong back vast global network innovative product portfolio update technology aftermarket business generate stable recur revenue notably delphi technology report strong first quarter result adjust earning share beat consensus mark cent be penny year quarter net revenue beat zack consensus estimate figure be year year report basis adjust basis such impressive result observe share delphi technology have decline industry rise year date basis drive delphi technology delphi technology have geographically diverse revenue base region wise derive revenue europe middle east africa emea north america asia pacific south america first quarter company be highly optimistic opportunity asia pacific region net sale region grow almost quarter increase level vehicle production region be encourage regional presence couple diversify innovative product portfolio update technology help delphi technology become solid choice original equipment manufacturer oem be oem be focuse increase efficiency expand global manufacturing footprint choose supplier global scale easily adapt regional variation additionally delphi technology be also optimistic opportunity aftermarket business aftermarket product portfolio offer extensive range solution include fuel injection electronic engine management maintenance test equipment vehicle diagnostic category lead aftermarket company include independent retailer wholesale distributor demand aftermarket product service depend grow number vehicle life cycle total mile cover replacement many aftermarket product be discretionary nature company generate stable recur revenue aftermarket business zack rank stock considerdelphi technology be zack rank buy stock see complete list today zack rank strong buy stock here other top rank stock broader business service sector include blucora bcor free report holding iqv free report aptiv aptv free report blucora sport zack rank holding aptiv carry zack rank long term expect earning share growth rate blucora holding aptiv be respectively hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
13,IQV,omnicom group inc omc free report be schedule report second quarter result jul open bell expect company top line do well back revenue growth most region lower tax rate be likely have positive impact omnicom earning observe share omnicom have gain year date compare zack composite gain top line improve year zack consensus estimate revenue be report quarter be peg indicate year year increase expect company witness top line growth most region region wise consensus estimate north america revenue indicate improvement year year same latin america be expect rise year year year year year year asia pacific year year euro other europe middle east africa be expect remain stable first quarter company revenue increase year year organic growth be quarter regional market revenue latin america increase year year asia pacific record increase revenue euro other europe improve record improvement however revenue north america reduce year year same middle east africa be earning likely grow tax reform tax cut job act reduce corporate tax rate significantly benefit omnicom earning be report quarter notably consensus estimate earning share ep be peg indicate year year growth first quarter earning increase year year company also enjoy lower income tax rate reduction income tax expense due successful resolution foreign tax claim first quarter full year company anticipate effective tax rate exclude potential tax benefit share base compensation model doesn suggest beatplease note accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp stock zack rank sell rate be best avoid especially have negative earning esp uncover best stock buy sell re report earning esp filter omnicom have zack rank earning esp stock considerhere be few stock broader business service sector investor consider model show have right combination element beat earning second quarter aptiv plc aptv free report have earning esp zack rank company be slate report quarterly number jul see complete list today zack rank stock here holding inc iqv free report have earning esp zack rank company be slate report quarterly result jul avis budget group inc car free report have earning esp zack rank company be expect report quarterly number aug hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
14,IQV,broadridge financial solution inc br free report recently launch cognitive marketing platform broadridge smart insight enable easy efficient distribution content prospect channel be wealth management solution integrate broadridge cloud ai dataset consumer demographic behavioral financial information secure multus channel platform platform feature auto identification prospect fit interest level engagement activity build ai automatically select best suit content prospect just right time be newest release company integrate wealth management solution product suite serve more financial advisor several wealth management firm steve scruton president broadridge advisor solution state be help client advisor become bionic leverage new technology datum scale transform business enrich customer engagement optimize efficiency generate growth observe share broadridge have surge year significantly outperform rally industry belong
15,IQV,prudent investment decision involve buy stock have solid prospect selling carry risk time be rational hold certain stock have enough potential be weigh tough market condition here discuss factset research system inc fds free report company have expect long term earning share growth rate moreover earning be expect register growth fiscal respectively year time share factset have gain outperform composite rise
16,IQV,aptiv plc aptv free report yesterday announce have inked deal purchase interconnect base provider custom engineer interconnect solution harsh environment application affiliate snow phipps group subject regulatory approval fulfillment customary close condition propose buyout be expect close end come heel aptiv acquisition south korea base provider engineer connector cable management solution kum jun glimpse aptiv price trend reveal stock have have impressive run bourse past month share aptiv have return significantly outperform industry gain say time frame signal power solution likely growpost deal closure operate independent business unit aptiv signal power solution segment segment design manufacture assemble electrical architecture vehicle include engineer component product wiring assembly harness connector cable management electrical center hybrid high voltage safety distribution system first quarter segment contribute largest chunk aptiv total revenue revenue segment increase year year billionkevin clark aptiv president chief executive officer state further establish aptiv market leader connectivity solution be strategic fit signal power solution segment acquisition have be key growth catalyst aptiv company have be continuously acquire investing company globally internationally expand capability strengthen market share increase geographic presence zack rank stock aptiv have zack rank buy see complete list today zack rank strong buy stock here other top rank stock broader business service sector include blucora bcor free report holding iqv free report paychex payx free report blucora sport zack rank holding paychex carry zack rank long term expect earning share growth rate blucora holding paychex be respectively more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
17,IQV,first century fox inc foxa free report share gain company settle lawsuit former employee fox news channel have sue company allege racial gender holding inc iqv free report decrease fda raise serious concern company datum related controlled substance prescription fentanylabaxis inc abax free report share jump animal health company zoetis inc zts free report agree buy cashshare teva pharmaceutical industry ltd teva free report rise warren buffet berkshire hathaway inc brk free report more double investment company
18,IQV,first quarter earning season have crossed half way mark earning revenue growth track reach highest level year accord latest earning preview company have already report result earning company increase same period last year higher revenue outpaced earning estimate exceed top line expectation proportion company beating ep revenue estimate be notably more company include member report result week bullish index total first quarter earning be expect increase higher revenue notably last report quarter witness earning growth increase revenue full year total earning be expect improve higher revenue rosy picture business servicesper report company business service sector be expect record top bottom line growth respectively notably zack sector end ongoing earning season double digit earning growth sector be business service usually sector be directly proportional broader economy be currently quite favorable fact rise gdp record low unemployment level strong job addition ease dollar momentum oil price be sign improvement economy turn boost sector performance trump business friendly policy include tax cut repeal regulation be additional tailwind stock watch earning automatic datum process inc adp free report business process outsource service provider report third quarter fiscal result zack consensus estimate company third quarter revenue be peg reflect year year growth same earning share stand indicate year year growth yet be report quarter company top line be expect benefit higher organic growth favorable foreign currency movement acquisition bottom line be likely be positively impact tax benefit result tax cut job act additionally automatic datum process have impressive earning surprise history have surpass estimate trail quarters average beat year time share zack rank buy company have gain compare industry rally see complete list today zack rank strong buy stock here republic service inc rsg free report solid waste collection transfer recycling disposal company report first quarter result consensus estimate first quarter revenue stand reflect year year growth top line be expect benefit higher internal growth buyout strong segmental performance consensus mark earning share be report quarter be peg cent indicate year year growth lower tax rate revenue growth be likely positively impact company bottom line republic service also have impressive earning surprise history have outpaced estimate trail quarters average positive surprise company carry zack rank sell share company have gain past year underperform industry rally aptiv plc aptv free report automotive technology solution provider report first quarter result zack consensus estimate company earning be peg reflect decline year quarter actual figure consensus mark revenue be peg reflect decline year quarter actual figure company however have impressive earning surprise history surpass estimate trail quarters average beat year time share zack rank have rally industry decline holding inc iqv free report integrate information technology enabled healthcare service company report first quarter result zack consensus estimate company earning revenue be peg respectively earning estimate compare year quarter actual figure reflect growth revenue estimate show year year improvement zack rank hold company earning surprise history have be impressive too company outpaced estimate trail quarters average beat company share have rally year industry decline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
19,IQV,investor be always look stock be poise beat earning season quintile transitional holding inc iqv free report be such company firm have earning come pretty soon event be shape quite nicely report be quintile transitional be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface iqv report fact most accurate estimate current quarter be currently share iqv compare broader zack consensus estimate share suggest analyst have very recently bump estimate iqv give stock zack earning esp head earning season quintile transitional holding inc price ep surprise quintile transitional holding inc price ep surprise quintile transitional holding inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give iqv have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead quintile transitional beat be card upcoming report hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
20,IQV,investor be always look stock be poise beat earning season holding inc iqv free report be such company firm have earning come pretty soon event be shape quite nicely report be be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface report fact most accurate estimate current quarter be currently share iqv compare broader zack consensus estimate share suggest analyst have very recently bump estimate iqv give stock zack earning esp head earning season quintile transitional holding inc price ep surprise quintile transitional holding inc price ep surprise quintile transitional holding inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give iqv have zack rank hold esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead beat be card upcoming report hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
21,IQV,week government other entity release economic report cover area economy retail sale housing international trade consumer sentiment fact virtually give day be anywhere handful report financial medium do cover usually focus headline number do deeper dive be unfortunate report often exist money make detail quickly be uncovered just extra few minute read example employment situation report detail sector see most new job labor force expansion one contract remember countless time report get right sector industry right time anybody else be talk fact still remember get housing early everybody else be stay far away possible see construction job continue rise report report report know housing market have turn be first alert housing recovery know look headline number obligatory sentence up many news site miss best part story not go extra mile paragraph well here be again more stock pick insight straight last week employment situation report last week show biggest job creation come industry construction last month professional business service last month private educational service last month manufacturing last month health care last month once report point right direction then plug appropriate sector industry capitalize information find best stock group be just very specific way do top analysis go screener zack com research wizard locate sector then industry interest then add favorite most successful stock pick criterium drill best one such zack rank strong buy buy market beating growth rate industry valuation upward earning estimate revision etc here be stock industry single biggest job creator last week employment report lii free report lennox construction man free report manpowergroup professional business service lope free report grand canyon education private educational service itw free report illinois tool work manufacturing quintile im holding health care profitable stock idea come time place instead wait next great stock fall lap actively search read few extra report then putt idea capable screener ll soon be amaze new pick come ll feel pretty smart find too research wizard be great place begin easy use everything be plain language very intuitive start trial research wizard today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today want more article author scroll top article click follow author button get email time new article be publish disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance
22,IQV,biopharma rally past year be wonder behold drive healthcare demographic exciting new science fantastic earning growth big cap trend appear poise continue strong several more year
23,IQV,science get new drug therapy fda gauntlet be full landmine investor be essential infrastructure company don have fda risk simply serve scientist get paid way
24,IQV,quintile transnational holding be year old health science company go public again last be largest pharmaceutical outsource company world annual revenue company be leader outsourced drug development service operate country
25,IQV,quintile have help develop commercialize top best selling drug mean client include big pharma name johnson johnson jnj free report pfizer pfe merck mrk well biotech giant amgen amgn free report gilead gild free report biogen idec biib free report
26,IQV,thousand health professional include mds complete datum base risk analytic local presence globe company promise demand customer be
27,IQV,unique combination person process technology help achieve more predictable outcome step way
28,IQV,provide professional information sale service pharmaceutical healthcare industry quintile have primary business segment product development pd integrate healthcare service ihs here help scientist healthcare entrepreneur navigate way market
29,IQV,project management
30,IQV,clinical monitoring service
31,IQV,strategic plan design service
32,IQV,consult service contract sale
33,IQV,market entry market exit
34,IQV,integrate channel management
35,IQV,patient engagement
36,IQV,market access
37,IQV,consult
38,IQV,brand scientific communication
39,IQV,medical education service
40,IQV,outcome observational service
41,IQV,much complete solution set healthcare pharmaceutical company be provide multus year contract drug information management marketing be such long campaign commercial health science require such constant accurate interface regulator
42,IQV,systematic growth
43,IQV,quintile doesn have explosive growth biotech company path launch blockbuster drug company have record double digit revenue growth average past decade
44,IQV,february report better expect fourth quarter result give guidance pleased investor result impressed revenue expectation lead
45,IQV,strength product development also beating bottom line
46,IQV,more importantly company issue consensus top line guidance growth adjust ep solid book bill metric product development integrate healthcare service analyst respond boost ep estimate year next
47,IQV,stand out quarter be strong new business growth segment time pd time ihs give company size analyst be impressed ability consistently book more new business deepen relationship client
48,IQV,analyst board
49,IQV,quarterly report wall street firm be force praise company raise ep estimate cause stock zack rank increase buy rating strong buy february here sampling analyst move
50,IQV,goldman sachs upgrade buy january price target raise
51,IQV,citi initiate coverage buy rating february
52,IQV,baird reiterate outperform rating feb raise pt
53,IQV,jpm reiterate overweight rating increase pt
54,IQV,william blair reiterate outperform note attractive valuation relative peer
55,IQV,well fargo reiterate outperform raise valuation range
56,IQV,institutional support
57,IQV,screening growth stock look sec filing misattribution investor find be buy come initial fundamental technical screen look big holder see be buy selling
58,IQV,stand owner be private equity firm still hold majority stake ipo bain capital tpg group big fundamental buyer last quarter be wellington management more double stake share just stake
59,IQV,enormous market
60,IQV,baird analyst note feb report client don have choose tool testing do be highly script law regulation practice give average year lifecycle development ever expand testing requirement glacial pace change think solution set be viable decade come
61,IQV,consider breadth global client base combine product service offer estimate total addressable market opportunity be expand breadth furious pace new science turn potential pharmaceutical treatment new business opportunity quintile continue grow pie very little competition
62,IQV,disclosure own share quintile zack follow money portfolio
63,IQV,kevin cook be senior stock strategist zack run follow money portfolio
